Aquestive Therapeutics (AQST) Non-Current Deffered Revenue (2019 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Non-Current Deffered Revenue of $19.1 million for Q1 2026, down 3.17% year-over-year from $19.7 million in Q1 2025, and down 1.4% quarter-over-quarter from $19.4 million in Q4 2025.
Aquestive Therapeutics (AQST) Non-Current Deffered Revenue (2019 - 2026) Analysis & Trends
Aquestive Therapeutics' Non-Current Deffered Revenue history runs 8 years deep, the most recent figure standing at $19.1 million for Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue fell 3.17% year-over-year to $19.1 million; the TTM figure through Mar 2026 stood at $19.1 million (down 3.17% YoY), while the FY2025 annual figure was $19.4 million, down 3.07% from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $19.1 million, down from $19.4 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $33.1 million in Q2 2023, with the low at $13.5 million in Q2 2022.
- The 5-year median for Non-Current Deffered Revenue is $20.0 million (2024), against an average of $23.5 million.
- The sharpest annual moves came in 2022 and 2025: Non-Current Deffered Revenue soared 341.13% in 2022, then plunged 38.22% in 2025.
- Aquestive Therapeutics' Non-Current Deffered Revenue stood at $31.4 million in 2022, then climbed by 2.95% to $32.3 million in 2023, then plunged by 38.15% to $20.0 million in 2024, then decreased by 3.07% to $19.4 million in 2025, then declined by 1.4% to $19.1 million in 2026.
- Business Quant data shows AQST's Non-Current Deffered Revenue at $19.1 million in Q1 2026, $19.4 million in Q4 2025, and $19.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Aquestive Therapeutics | 554.35 Mn | 554.35 Mn | 9.80 Mn | 18.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.85 Mn |
| Mar 31, 2026 | 19.12 Mn |
| Dec 31, 2025 | 19.39 Mn |
| Sep 30, 2025 | 19.66 Mn |
| Jun 30, 2025 | 19.94 Mn |
| Mar 31, 2025 | 19.74 Mn |
| Dec 31, 2024 | 20.01 Mn |
| Sep 30, 2024 | 20.27 Mn |
| Jun 30, 2024 | 21.76 Mn |
| Mar 31, 2024 | 31.96 Mn |
| Dec 31, 2023 | 32.35 Mn |
| Sep 30, 2023 | 32.73 Mn |
| Jun 30, 2023 | 33.12 Mn |
| Mar 31, 2023 | 33.04 Mn |
| Dec 31, 2022 | 31.42 Mn |
| Sep 30, 2022 | 17.62 Mn |
| Jun 30, 2022 | 13.49 Mn |
| Mar 31, 2022 | 13.89 Mn |
| Dec 31, 2021 | 7.12 Mn |
| Sep 30, 2021 | 7.32 Mn |